PON2 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, PON2 knockdown enhanced apoptosis-related death of chronic myeloid leukemia K562 cells receiving treatment with Bcr-Abl tyrosine-kinase inhibitor imatinib, while the opposite effect was induced upon enzyme upregulation [45].